• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

帕金森病治疗变化相关的临床变量:REASON研究纵向阶段的结果

Clinical variables associated with treatment changes in Parkinson's disease: results from the longitudinal phase of the REASON study.

作者信息

Abbruzzese Giovanni, Barone Paolo, Ceravolo Roberto, Fabbrini Giovanni, Lessi Patrizia, Ori Alessandra, Simoni Lucia, Tinazzi Michele, Antonini Angelo

机构信息

DINOGMI, Centro Parkinson, Università degli Studi di Genova, Largo Daneo 3, 16132, Genoa, Italy,

出版信息

Neurol Sci. 2015 Jun;36(6):935-43. doi: 10.1007/s10072-014-2060-6. Epub 2015 Jan 7.

DOI:10.1007/s10072-014-2060-6
PMID:25564417
Abstract

To assess over a period of 9 months in a sample of Italian Parkinson's disease (PD) patients reasons leading the neurologist to modify dopaminergic treatment and patients' causes of dissatisfaction with ongoing therapy. To evaluate the influence of disease severity on therapy persistence. A disease severity balanced sample of PD patients with stable anti-parkinsonian drugs (APD) treatment was enrolled and evaluated every 3 months. Patients requiring APD treatment modifications were discontinued from the study. The probability to modify APD treatment is greater for higher motor (UPDRS scores) and non-motor symptoms (NMSS score) severity. Both from neurologist's and patient's perspective, motor symptoms were the main determinants underlying APD treatment modifications. Non-motor symptoms were cause of dissatisfaction with ongoing APD treatment for 52 % of the patients, while only 36 % of the neurologists considered these as valid reasons for therapy change. REASON is the first study in PD patients that prospectively examined reasons driving APD treatment changes. Results show that the disease severity significantly increases the probability of APD treatment change. Patients attribute greater relevance than neurologists to non-motor symptoms as reason requiring treatment changes. This confirms that patient and neurologist perceptions only partially overlap.

摘要

为了在9个月的时间里评估意大利帕金森病(PD)患者样本中,导致神经科医生调整多巴胺能治疗的原因以及患者对当前治疗不满的原因。为了评估疾病严重程度对治疗持续性的影响。招募了一组帕金森病患者,他们接受稳定的抗帕金森病药物(APD)治疗,疾病严重程度均衡,每3个月进行一次评估。需要调整APD治疗的患者退出研究。运动(统一帕金森病评定量表评分)和非运动症状(非运动症状评分)严重程度越高,调整APD治疗的可能性越大。从神经科医生和患者的角度来看,运动症状都是APD治疗调整的主要决定因素。非运动症状是52%的患者对当前APD治疗不满的原因,而只有36%的神经科医生认为这些是治疗改变的有效理由。REASON是第一项对帕金森病患者前瞻性研究驱动APD治疗改变原因的研究。结果表明,疾病严重程度显著增加了APD治疗改变的可能性。患者比神经科医生更将非运动症状视为需要治疗改变的原因。这证实了患者和神经科医生的认知仅部分重叠。

相似文献

1
Clinical variables associated with treatment changes in Parkinson's disease: results from the longitudinal phase of the REASON study.帕金森病治疗变化相关的临床变量:REASON研究纵向阶段的结果
Neurol Sci. 2015 Jun;36(6):935-43. doi: 10.1007/s10072-014-2060-6. Epub 2015 Jan 7.
2
Reasons driving treatment modification in Parkinson's disease: results from the cross-sectional phase of the REASON study.导致帕金森病治疗改变的原因:REASON 研究横断面阶段的结果。
Parkinsonism Relat Disord. 2013 Dec;19(12):1130-5. doi: 10.1016/j.parkreldis.2013.08.006. Epub 2013 Aug 28.
3
Characterizing advanced Parkinson's disease: OBSERVE-PD observational study results of 2615 patients.晚期帕金森病的特征:2615例患者的OBSERVE-PD观察性研究结果
BMC Neurol. 2019 Apr 2;19(1):50. doi: 10.1186/s12883-019-1276-8.
4
Actigraphy monitoring of symptoms in patients with Parkinson's disease.帕金森病患者症状的活动监测。
Physiol Behav. 2013 Jul 2;119:156-60. doi: 10.1016/j.physbeh.2013.05.044. Epub 2013 Jun 6.
5
A longitudinal study of non-motor symptom burden in Parkinson's disease after a transition to expert care.帕金森病患者转至专家护理后非运动症状负担的纵向研究。
Parkinsonism Relat Disord. 2015 Aug;21(8):843-7. doi: 10.1016/j.parkreldis.2015.04.017. Epub 2015 May 16.
6
Assessing the non-motor symptoms of Parkinson's disease: MDS-UPDRS and NMS Scale.评估帕金森病的非运动症状:MDS-UPDRS 和 NMS 量表。
Eur J Neurol. 2015 Jan;22(1):37-43. doi: 10.1111/ene.12165. Epub 2013 Apr 22.
7
Clinical manifestations of nonmotor symptoms in 1021 Japanese Parkinson's disease patients from 35 medical centers.来自35个医疗中心的1021名日本帕金森病患者非运动症状的临床表现。
Parkinsonism Relat Disord. 2017 May;38:54-60. doi: 10.1016/j.parkreldis.2017.02.024. Epub 2017 Feb 21.
8
International study on the psychometric attributes of the non-motor symptoms scale in Parkinson disease.帕金森病非运动症状量表心理测量属性的国际研究。
Neurology. 2009 Nov 10;73(19):1584-91. doi: 10.1212/WNL.0b013e3181c0d416.
9
Subthalamic Nucleus Deep Brain Stimulation Modulate Catecholamine Levels with Significant Relations to Clinical Outcome after Surgery in Patients with Parkinson's Disease.丘脑底核深部脑刺激调节帕金森病患者术后儿茶酚胺水平,且与临床结局显著相关。
PLoS One. 2015 Sep 22;10(9):e0138462. doi: 10.1371/journal.pone.0138462. eCollection 2015.
10
Impact of non-motor symptoms on health-related and perceived quality of life in Parkinson's disease.帕金森病非运动症状对健康相关和感知生活质量的影响。
J Neurol Sci. 2013 Sep 15;332(1-2):136-40. doi: 10.1016/j.jns.2013.07.005. Epub 2013 Jul 25.

引用本文的文献

1
Treatment Satisfaction and Its Influencing Factors in Parkinson's Disease: A Web-Based Survey of Patients and Physicians in Clinical Practice in Japan.帕金森病的治疗满意度及其影响因素:日本临床实践中患者和医生的网络调查
Parkinsons Dis. 2022 Feb 23;2022:2732021. doi: 10.1155/2022/2732021. eCollection 2022.
2
Criteria for identification of advanced Parkinson's disease: the results of the Italian subgroup of OBSERVE-PD observational study.识别晚期帕金森病的标准:观察性帕金森病研究(OBSERVE-PD)意大利子组的研究结果。
BMC Neurol. 2022 Jan 28;22(1):41. doi: 10.1186/s12883-022-02554-z.
3
Patient and physician perceptions of disease management in Parkinson's disease: results from a US-based multicenter survey.

本文引用的文献

1
Reasons driving treatment modification in Parkinson's disease: results from the cross-sectional phase of the REASON study.导致帕金森病治疗改变的原因:REASON 研究横断面阶段的结果。
Parkinsonism Relat Disord. 2013 Dec;19(12):1130-5. doi: 10.1016/j.parkreldis.2013.08.006. Epub 2013 Aug 28.
2
Systematic review of levodopa dose equivalency reporting in Parkinson's disease.帕金森病左旋多巴剂量等效报告的系统评价。
Mov Disord. 2010 Nov 15;25(15):2649-53. doi: 10.1002/mds.23429.
3
Drug therapies for Parkinson's disease: A database analysis of patient compliance and persistence.
帕金森病患者及医生对疾病管理的认知:一项基于美国的多中心调查结果
Neuropsychiatr Dis Treat. 2019 May 30;15:1487-1495. doi: 10.2147/NDT.S196930. eCollection 2019.
4
Disease progression in Parkinson subtypes: the PPMI dataset.帕金森亚型中的疾病进展:PPMI 数据集。
Neurol Sci. 2018 Nov;39(11):1971-1976. doi: 10.1007/s10072-018-3522-z. Epub 2018 Aug 14.
5
Transgenerational latent early-life associated regulation unites environment and genetics across generations.跨代潜在早期生命关联调控将环境和遗传跨代统一起来。
Epigenomics. 2016 Mar;8(3):373-87. doi: 10.2217/epi.15.117. Epub 2016 Mar 7.
帕金森病的药物治疗:患者依从性和持续性的数据库分析
Am J Geriatr Pharmacother. 2010 Aug;8(4):374-83. doi: 10.1016/j.amjopharm.2010.08.001.
4
Therapy adherence issues in Parkinson's disease.帕金森病的治疗依从性问题。
J Neurol Sci. 2010 Feb 15;289(1-2):115-8. doi: 10.1016/j.jns.2009.08.053. Epub 2009 Sep 29.
5
Treatments for Parkinson disease--past achievements and current clinical needs.帕金森病的治疗——过去的成就与当前的临床需求
Neurology. 2009 Feb 17;72(7 Suppl):S65-73. doi: 10.1212/WNL.0b013e31819908ce.
6
Treatment of Parkinson's disease: a survey of patients and neurologists.帕金森病的治疗:患者与神经科医生的调查
Clin Drug Investig. 2007;27(3):207-18. doi: 10.2165/00044011-200727030-00004.
7
Diagnostic criteria for Parkinson disease.帕金森病的诊断标准。
Arch Neurol. 1999 Jan;56(1):33-9. doi: 10.1001/archneur.56.1.33.